1st semester farmaco notes
Page 1: Anticholinesterase Drugs
Physostigmine (Eserine)
Subclass: Anticholinesterase, carbamic acid ester.
Receptors: Targets cholinesterase at the acetylcholine binding site.
Effects:
Reversible and short-acting.
Lipophilic; crosses the blood-brain barrier (BBB).
Increases acetylcholine levels at synaptic clefts affecting both muscarinic and nicotinic receptors.
Clinical Uses:
Used as conjunctival drops for glaucoma, less preferred than pilocarpine due to irritation.
Rarely used systemically due to high toxicity.
Adverse Reactions:
Toxic effects can cause excessive salivation, sweating, diarrhea, bradycardia, bronchospasm, agitation, or seizures.
Neostigmine
Subclass: Anticholinesterase, carbamic acid ester.
Receptors: Inhibits cholinesterase at the acetylcholine binding site.
Effects:
Short-acting and reversible.
Poorly absorbed from the GI tract and does not cross the BBB, so no CNS effects.
Increases availability of acetylcholine at neuromuscular junctions and autonomic synapses.
Clinical Uses:
Primary: Treatment for myasthenia gravis (orally).
Secondary: Treats postoperative bladder or intestinal atony, antidote for curariform poisoning, diagnostic tests for myasthenia gravis.
Adverse Reactions:
Gastrointestinal: Abdominal cramps, diarrhea.
Cardiovascular: Bradycardia.
Respiratory: Bronchospasm.
Contraindications: Intestinal/urinary obstruction, asthma, bradycardia, active peptic ulcers.
Page 2: Organophosphates and Edrophonium
Organophosphates (e.g., Parathion, Malathion, Soman, Sarin)
Subclass: Anticholinesterase, organophosphate derivatives.
Receptors: Irreversibly bind to cholinesterase at acetylcholine binding site.
Effects:
Cause irreversible inhibition of cholinesterase, leading to the accumulation of acetylcholine.
Crosses the BBB causing systemic and CNS effects.
Clinical Uses:
Primarily used as insecticides and in chemical warfare; not used medically.
Adverse Reactions (Toxicity):
Muscarinic Effects: Miosis, bradycardia, excessive salivation, sweating, diarrhea.
Nicotinic Effects: Muscle fasciculations, convulsions, paralysis, respiratory failure.
CNS Effects: Seizures, agitation, coma.
Management of Poisoning:
Atropine in high doses, cholinesterase reactivators (e.g., pralidoxime, effective before enzyme aging).
Edrophonium
Subclass: Anticholinesterase, alcohol derivative.
Receptors: Reversibly inhibits cholinesterase.
Effects:
Very short-acting, temporarily increases acetylcholine levels at cholinergic synapses.
Primarily affects the neuromuscular junction.
Clinical Uses:
Diagnostic testing for myasthenia gravis by temporarily improving symptoms.
Used to manage paroxysmal supraventricular tachycardia by slowing heart rate.
Adverse Reactions:
Similar to other anticholinesterases: gastrointestinal discomfort, bradycardia, excessive secretions.
Short duration limits systemic adverse effects.
Page 3: Tacrine and Donepezil
Tacrine and Donepezil
Subclass: Anticholinesterase, CNS-acting agents.
Receptors: Selectively inhibit acetylcholinesterase in the brain.
Effects:
Enhance acetylcholine levels in CNS by inhibiting breakdown.
Improve cognitive function in conditions with cholinergic deficits.
Clinical Uses:
Treatment of Alzheimer’s disease.
Adverse Reactions:
Gastrointestinal: Nausea, vomiting, diarrhea.
CNS: Headache, dizziness, insomnia.
Tacrine associated with hepatotoxicity, limiting its use compared to Donepezil.
Page 4: Neostigmine and Edrophonium Testing
Anticholinesterase: Neostigmine
Effects:
Effects mediated through nicotinic receptors on striated muscle; muscarinic receptors mediate other effects.
Blocking muscarinic receptors with atropine can antagonize gastrointestinal and urinary bladder effects.
Useful in treating myasthenia gravis or as a decurarizing agent when combined with atropine.
Atropine improves tolerability.
Administration:
IV administration for rapid relief of muscle fatigue in myasthenia gravis.
Transition to oral maintenance treatment over an indefinite period.
Edrophonium
Testing:
A positive test leads to maintenance with neostigmine or pyridostigmine, preferred due to shorter action.
Administration:
Administered IV, increases availability of Ach at heart level, causing vagal modifications.
Page 5: Organophosphate Usage and Toxicity Management
Organophosphates
Uses:
Examples include Parathion, Malathion, Soman, Sarin; not used therapeutically, employed as insecticides/chemical warfare agents.
Toxicity Management:
Atropine IV: 1-2 mg every 5-10 minutes until signs of atropinization appear.
Cholinesterase reactivators: Restore nicotinic function at neuromuscular synapses and prevent CNS complications.
Physical decontamination: Removal of clothing, washing skin, gastric lavage if ingestion occurs.
Supportive measures: Tracheobronchial aspiration, assisted respiration, maintaining BP, anticonvulsants for seizures.
Page 6: Adrenergic System Overview
Adrenergic System
Receptor Blockades and Stimulations:
M-: Blocks muscarinic receptors (non-selective).
M1-: Blocks M1 receptors.
Nn+: Stimulates nicotinic neuronal receptors.
Adrenergic Medications and Mechanisms
1. Adrenaline
Effects:
α1: Vasoconstriction in skin/mucosal blood vessels.
β2: Vasodilation in skeletal muscle/renal vessels, redirecting circulation.
Stimulates cardiac activity (β1). Splenic contraction increases circulating blood volume.
Clinical Uses:
Treats anaphylaxis, bronchospasm, cardiac arrest.
2. Noradrenaline
Effects:
Potent vasoconstriction (α1), increases BP and cardiac output despite vagal inhibition.
Page 7: Sympathomimetics
Sympathomimetics
1. Direct Sympathomimetics
Examples: Cocaine, tricyclic antidepressants, MAOIs.
Mechanism: Prevent reuptake/metabolism of catecholamines.
Effect: Potentiate adrenergic stimulation.
2. Indirect Sympathomimetics
Examples: Ephedrine, amphetamine.
Mechanism: Facilitate catecholamine release/releases; inhibit reuptake.
Effects: Increase catecholamine availability, stimulating adrenergic receptors.
3. Selective β2 Sympathomimetics
Clinical Uses:
Oral for reducing uterine contractility, treating bronchospasm/asthma.
Precaution:
Avoid double β-blockers to prevent excessive effects.
Page 8: Adrenergic Receptor Functions
Catecholaminergic Receptors
α1 Receptors
Location: Smooth muscle in blood vessels, iris, urinary bladder.
Effects:
Vasoconstriction, urinary sphincter contraction, pupil dilation.
Clinical Relevance:
Treat hypotension, nasal congestion, BP maintenance during surgeries.
α2 Receptors
Location: Presynaptic nerve terminals, CNS.
Effects:
Inhibits norepinephrine release, reducing heart rate and BP, provides sedation.
Clinical Relevance:
Treat hypertension, ADHD, sedation in chronic pain.
β1 Receptors
Location: Heart (SA/AV nodes), kidneys.
Effects:
Increased heart rate, contractility, and conduction velocity; stimulates renin secretion.
Clinical Relevance:
β1 agonists for acute heart failure, cardiogenic shock; antagonists manage hypertension.
β2 Receptors
Location: Smooth muscle of bronchi, blood vessels in skeletal muscle, uterus.
Effects:
Bronchodilation, vasodilation, uterine relaxation.
Clinical Relevance:
First-line treatment for asthma/COPD.
β3 Receptors
Location: Adipose tissue, urinary bladder, brain.
Effects:
Lipolysis, bladder relaxation.
Clinical Relevance:
Used to treat overactive bladder, potential obesity treatments.
Page 9: Direct Adrenomimetics
Direct Sympathomimetic Adrenomimetics
Adrenaline (Epinephrine)
Effects:
Increases heart rate, myocardial contractility, causes vasodilation in skeletal muscles.
Indications include anaphylactic shock, cardiac arrest, severe asthma attacks.
Adverse Effects:
Palpitations, anxiety, tremors, hypertension, arrhythmias.
Norepinephrine (Noradrenaline)
Effects:
Causes vasoconstriction and modest increases in heart rate and contractility.
Indications: acute hypotension, septic/cardiogenic shock.
Adverse Effects:
Peripheral ischemia, bradycardia (vagal reflex), hypertension.
Dopamine
Effects:
Low Doses: Renal vasodilation; moderate doses: β1 stimulation; high doses: α1 stimulation.
Indications include acute heart failure/cardiogenic shock.
Adverse effects: Tachycardia, arrhythmias, hypertension.
Isoproterenol (Isoprenaline)
Effects:
Stimulates β-adrenergic receptors, causing vasodilation and increased heart rate.
Indications include bradyarrhythmias, increasing heart rate in heart failure situations.
Adverse effects: Palpitations, tachycardia, headache.
Page 10: Selective Sympathomimetics
Sympathomimetics – Alpha-1 Selective
Phenylephrine
Clinical Uses:
Treatment of shock conditions; nasal/conjunctival decongestion.
Effects: Similar to norepinephrine.
Xylometazoline and Oxymetazoline
Clinical Uses:
Nasal decongestants.
Adverse Reactions:
Rebound congestion (medication-induced rhinitis).
Receptor Activity:
Primarily act on α-1 receptors for vasoconstriction, stimulating α-2 receptors as well.
Page 11: Alpha-2 Selective Sympathomimetics
Sympathomimetics – Alpha-2 Selective
Clonidine
Administration:
IV: Short-term BP increase; long-term decrease.
Oral: Reduces long-term BP.
Effects:
Inhibits catecholamine release, providing indirect sympatholytic effects.
Clinical Uses:
Treatment of arterial hypertension.
Direct Sympathomimetics – Beta Selective
Isoprenaline (Isoproterenol)
Administration:
Inactive orally, crosses BBB poorly.
Effects:
Bronchodilation, improved myocardial contractility, increases heart rate, induces vasodilation in β2 areas.
Clinical Uses:
Asthma management, A-V conduction disorders, shock management.
Adverse Reactions:
Increased myocardial oxygen consumption, tachycardia, arrhythmias.
Salbutamol, etc.
Administration:
Emergency routes: IV infusion, IM, or oral.
Effects:
Bronchodilation, vasodilation, uterine relaxation.
Clinical Uses:
Asthma, uterine contractions management.
Adverse Reactions:
Low-intensity cardiac effects; CNS excitability.
Page 12: Salmeterol and Long-Acting Beta Agonists
Salmeterol, Formoterol
Effects:
Long-lasting effect; do not decongest bronchial mucosa.
Clinical Uses:
Prophylaxis for asthma attacks.
Dobutamine
Administration:
Racemic mixture.
Effects:
Stimulates β1 receptors, increasing cardiac contractility, minimal heart rate increase, improves cardiac output.
Clinical Uses:
Shock management, particularly cardiogenic shock. Indirect sympathomimetics.
Page 13: Indirect Sympathomimetics and Ephedrine
Indirect Sympathomimetics
Ephedrine
Generalities:
Type: Alkaloid, low polarity, crosses BBB; resistant to sulfation and COMT.
Effects and Clinical Uses:
Decongestant, historical use in asthma; lower intensity with longer duration, includes CNS effects.
Page 14: Other Indirect Sympathomimetics
Naphazoline
Generalities:
Not specified as polar or non-polar; well absorbed in GI.
Clinical Uses:
Decongestant for nasal/conjunctival mucosa.
Amphetamine
Generalities:
CNS effects: increases excitability; reduces fatigue, appetite suppression.
Clinical Uses:
Treatment for ADHD, improves focus and physical effort.
Adverse Reactions:
Anxiety, euphoria, addiction potential.
Page 15: Cocaine and Antidepressants
Cocaine
Generalities:
Local anesthetic, non-polar.
Clinical Uses:
Inhibit NET activity, increasing catecholamine availability.
Adverse Reactions:
Peripheral reactions, necrosis from vasoconstriction.
Antidepressants
Generalities:
Types: Tricyclic antidepressants, SSRIs, SNRIs.
Absorption, hepatic binding; clinical uses ranging from depression to ADHD.
Page 16 and onwards
Non-Selective Alpha Blockers, Selective Alpha-1 Blockers, and Neuroleptics
Mechanisms, Clinical Uses, and Adverse Effects are discussed as preceding classes of medications sandwiching Beta Blockers then Psychiatric Medications and their purported physiological mechanisms, mechanisms of receptor action, dosage, clinical indications, and potential side effects.
Extend contents by mapping relevant pharmacological interactions in short for clarity from the contents spanning -
Beta-Adrenergic Blockers: Propranolol characteristics and uses.
Atypical Antipsychotics overview.
Antidepressant classes and comparative benefits.